Physician profile
John F Dombrowski
NPI 1154329126
$3,173.55
in general payments reported to CMS, 2019-2025
13 companies · $291 in 2025
The $291 reported for 2025 was more than what 79% of Addiction Medicine (Anesthesiology) providers received nationally (typical 2025 total: $133).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $200 · 2021: $337 · 2022: $192 · 2023: $1,654 · 2024: $67.09 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,068 · Food and Beverage: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,068.18 |
| Food and Beverage | $944.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,513.73 | 2022-2025 | Infinion 16, Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $384.91 | 2019-2023 | Proclaim, Eterna |
| Indivior INC. | $313.61 | 2023-2025 | Sublocade |
| Stimwave Technologies Incorporated | $294.54 | 2019-2020 | |
| Medtronic, INC. | $253.30 | 2021-2023 | Intellis Adaptivestim |
| Pacira Pharmaceuticals Incorporated | $137.14 | 2023 | Zilretta, Iovera, Exparel |
| Painteq LLC | $101.38 | 2021 | |
| Pfizer INC. | $53.11 | 2020 | |
| Lilly USA, LLC | $41.21 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $33.02 | 2025 | |
| Assertio Therapeutics, INC. | $21.09 | 2019 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Electronic Waveform Lab, INC. | $5.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dombrowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.